COMPARISON OF RP-HPLC AND UV SPECTROPHOTOMETRIC METHODS FOR ESTIMATION OF HALOPERIDOL IN PURE AND PHARMACEUTICAL FORMULATION
An accurate, precise, sensitive and reproducible High-performance liquid chromatographic (HPLC) and UV spectrophotometric methods were developed and validated for the quantitative determination of haloperidol (HPD) in bulk drug and pharmaceutical formulation. Different analytical performance parameters such as linearity, precision, accuracy, specificity, limit of detection (LOD) and limit of quantification (LOQ) were determined according to International Conference on Harmonization ICH Q2B guidelines. The RP-HPLC method was developed by the isocratic technique on a reversed-phase Thermo C18 (250 × 4.6 mm, 5µm) column with mobile phase consisting of Methanol: Acetonitrile (50:50v/v) at flow rate of 1.0 ml/min. The retention time for HPD was 2.238±0.3min. The UV spectrophotometric determinations were performed at 244 nm using 80% methanol as a solvent. The linearity range for HPD was 5-25 μg/ml for both HPLC and UV method. The linearity of the calibration curves for each analyte in the desired concentration range was good (r2 >0.999) by both the HPLC and UV methods. The method showed good reproducibility and recovery with percent relative standard deviation less than 2%. Moreover, the accuracy and precision obtained with HPLC co-related well with the UV method which implied that UV spectroscopy can be a cheap, reliable and less time consuming alternative for chromatographic analysis. The proposed methods are highly sensitive, precise and accurate and hence successfully applied for determining the assay and in vitro dissolution of a marketed formulation.
Keywords: HPLC, UV Spectrophotometry, Haloperidol, Pharmaceutical formulation, Method validation, Quantitative analysis
2. Gajski G, Gerić M, Garaj-Vrhovac V. Evaluation of the in vitro cytogenotoxicity profile of antipsychotic drug haloperidol using human peripheral blood lymphocytes, Environmental Toxicology and Pharmacology, 2014; 38(1):316-24.
3. Benvegnú DM, Barcelos RC, Boufleur N, Reckziegel P, Pase CS, Ourique AF. Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats, European Journal of Pharmaceutics and Biopharmaceutics, 2011; 77(2):332-336.
4. Forsman AO. Individual variability in response to haloperidol, Journal of the Royal Society of Medicine, 1976; 69(1):9-13.
5. Rahman N, Khatoon A, Rahman H. Studies on the development of spectrophotometric method for the determination of haloperidol in pharmaceutical preparations, Química Nova, 2012; 35(2):392-397.
6. Indian Pharmacopoeia, Vol. 1 New Delhi, The Controller of publication, Government of India 2010; p. 1435.
7. British Pharmacopoeia, Vol. 1 (online version). London, The British Pharmacopoeia commission; 2012.
8. Fang J, Gorrod JW. High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations, Journal of Chromatography A, 1993; 614:267.
9. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update, Clinical Pharmacokinetics 1999; 37:435.
10. Lea AR, Hailey DM, Drugged PR. Analysis of haloperidol tablets by high-performance liquid chromatography-an inter-laboratory study, Journal of Chromatography A 1982; 250:35–42.
11. Imran A, Hassan YA. Fast determination of haloperidol in pharmaceutical preparations using HPLC with a monolithic silica column, J Liquid chromatography and related Technologies 2005; 28 Suppl 20:3169-79.
12. Fang J, Gorrod JW. High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations, Journal of Chromatography B Biomedical Sciences and Applications, 1993; 614 Suppl 2:267–273.
13. Trabelsi H, Bouabdallah S, Bouzouita K, Santa F. Determination and degradation study of haloperidol by high performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2002; 29 Suppl 4:649–657.
14. Monser L, Trablesi H. A rapid LC method for the determination of haloperidol and its degradation products in pharmaceuticals using a porous graphitic carbon column, J Liquid chromatography and related Technologies, 2003; 26 Suppl 2:267-271.
15. Xu X, Stewart JT. HPLC analysis of haloperidol and its related compound in the drug substance and a tablet dosage form using a non-porous silica octadecylsilane column, J Liquid chromatography and related Technologies, 1999; 22 Suppl 12:1857-1866.
16. Patela YP, Dhorda UJ, Sundaresan M. A comparative study using HPLC and packed column supercritical fluid chromatography for the assay of three anti-psychotic dosage forms, Talanta, 1998; 47 Suppl 3:625–630.
17. Sane RT, Ghadge JK, Jain AB, Vaidya AT, Kotwal SS. RP-HPLC estimation of haloperidol and propantheline bromide in tablets or capsules. Indian Drugs 1992; 29:240-4.
18. Water S, Bauer S, Roots I, Brockmoller J. Quantification of the antipsychotics flupentixol and haloperidol in human serum by high - performance liquid chromatography with ultraviolet detection, Journal of Chromatography B Biomedical Sciences and Applications, 1998; 720 Suppl 1-2:231–237.
19. Arinobu T, Hattori H, Iwai M, It A, Kumazawa T, Suzuki O, Seno H. Liquid chromatographic–mass spectrometric determination of haloperidol and its metabolites in human plasma and urine, Journal of Chromatography B Biomedical Sciences and Applications, 2002; 776 Suppl 1:107–113.
20. Janicki CA, Ko CT. Haperidol. In: Florey, K. (ed.). Analytical profile of drug substances. New York: Academic Press, 1991; 9:346-356.
21. Wate SP, Borkar AA. Simultaneous spectrophotometric estimation of haloperidol and trihexyphenidyl HCL in tablets, Indian Journal of Pharmaceutical Sciences, 2010; 72 Suppl 2:265-267.
22. Yasir M, Sara UVS. Development and validation of UV spectrophotometric method for the estimation of haloperidol, British Journal of Pharmaceutical Research, 2014; 4(11):1407-1415.
23. Chinese Pharmacopoeia. Chinese Pharmacopoeia Commission. Beijing: Chemical Industry Press, 2005. p.469.
24. Sigrid M, Loreto P, Mario V, Carmen GG, Marta DD. Quantitative determination of haloperidol in tablets by high performance thin-layer chromatography, Journal of Separation Science, 2007; 30(7):772-777.
25. Mojtaba S, Leila SD, Zahra T, Soheila H. 19F NMR as a powerful technique for the assay of anti-psychotic drug haloperidol in human serum and pharmaceutical formulations, Journal of Pharmaceutical and Biomedical Analysis, 2007; 43(3):1116-1121.
26. El-Desoky HS, Ghoneim MM. Assay of the anti-psychotic drug haloperidol in bulk form, pharmaceutical formulation and biological fluids using square-wave adsorptive stripping voltammetry at a mercury electrode, Journal of Pharmaceutical and Biomedical Analysis, 2005; 38(3):543-550.
27. European Pharmacopoeia. Strasbourg: Council of Europe, 2002. p. 1288-1289.
28. International Conference on Harmonisation (2005) Validation of analytical procedures: Text and Methodology, Geneva, Switzerland.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).